INHBE-3

Asset

GalNAc-conjugated siRNA silences hepatic INHBE, lowering Activin E and modulating adipocyte lipolysis.

Stage
Preclinical
Modality
Oligonucleotide
Target
Lipid and ceramide metabolism
1
Indication
0
Trials
1
Developer

Indications

1
  • Obesity

    Preclinical, doi.org, 5 Jun 2026

In the full profile

  • Targets and what it contains3
  • Owner and partners1
  • Evidence for its targets4
  • Competitors12
  • Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets